Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | PDE9A | O76083 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.43 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.43 |
| ▸ | DCK | P27707 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358056 | 0.89 | CYP3A4 (0.49) | CYP3A4GPR119PDE9ASLC2A1SLC2A2 | |
| SCHEMBL1128304 | 0.88 | CYP3A4 (0.50) | CYP3A4GPR119PDE9ACYP2C9NR3C1 | |
| SCHEMBL1128370 | 0.88 | CYP3A4 (0.65) | CYP3A4GPR119SLC2A1SLC2A2SLC2A3 | |
| SCHEMBL1128492 | 0.85 | CYP3A4 (0.45) | CYP3A4GPR119PDE9ASLC2A1SLC2A2 | |
| SCHEMBL1128408 | 0.84 | CYP3A4 (0.53) | CYP3A4GPR119SLC2A1SLC2A2SLC2A3 | |
| SCHEMBL1128671 | 0.84 | CYP3A4 (0.53) | CYP3A4GPR119SLC2A1SLC2A2SLC2A3 | |
| SCHEMBL1128314 | 0.83 | GPR119 (0.54) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL4360977 | 0.82 | BTK (0.46) | CYP3A4GPR119PDE9ASLC2A1SLC2A2 | |
| SCHEMBL1128458 | 0.80 | CYP3A4 (0.53) | CYP3A4GPR119PDE9ASLC2A1SLC2A2 | |
| SCHEMBL1128851 | 0.78 | CYP3A4 (0.60) | CYP3A4GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CYP3A4 1503/4885GPR119 1/4885PDE9A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.